Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30640773 | 0.93 | CASP3 (0.49) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL24579357 | 0.93 | CASP3 (0.49) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL24579361 | 0.92 | CASP3 (0.47) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL29866548 | 0.85 | CASP3 (0.52) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL23629983 | 0.85 | CASP3 (0.52) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL29696650 | 0.85 | KMT2A (0.51) | CASP3KMT2AMDM2 | |
| SCHEMBL23629985 | 0.85 | CASP3 (0.52) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL23629988 | 0.85 | CASP3 (0.52) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL29696743 | 0.85 | CASP3 (0.47) | CASP3KMT2AMEN1CTSLCTSB | |
| SCHEMBL29696679 | 0.84 | CASP3 (0.47) | CASP3KMT2ACTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-18 | — | — | US | disclosed |
| EP-4269422-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116615411-A | Process for producing peptide compound containing N-substituted amino acid residue | 中外制药株式会社 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022138891-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | 中外製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124517-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND CONTAINING N-SUBSTITUTED-AMINO ACID RESIDUE | VIP, NPEPPS, ANPEP | CASP3 3884/4885KMT2A 2123/4885MEN1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.